Circular Genomics and Altoida are pairing a 10-minute self-administered cognitive assessment with a circular RNA blood test in a sequential diagnostic workflow, placing first-line screening in primary care rather than specialist clinics. The cognitive app flags functional change; the blood test confirms the underlying neurodegenerative biology. With disease-modifying drugs most effective early, diagnostic throughput—not drug availability—is positioned as the limiting factor in preserving cognitive healthspan.
Key Points
- Ten-minute cognitive app triages patients before confirmatory circRNA blood testing
- circRNA signature predicts symptomatic progression years before clinical onset
- An estimated 200 million people have undiagnosed mild cognitive impairment
Longevity Analysis
Neurodegeneration accumulates silently for years while the signals it produces—slight changes in motor timing, speech, spatial navigation—go unread or get attributed to normal aging. Pairing functional performance with circulating molecular markers improves the fidelity of that interpretation, catching drift in how the brain and nervous system operate before structural loss becomes irreversible. The constraint on extending cognitive years is less about novel therapeutics than about diagnostic pathways people will realistically complete, at an interval frequent enough to matter.
Original published by Longevity.Technology, by Kyle Umipig.